Valvular & structural heart disease
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR
Authors' conclusion
Edoxaban compared to VKA was associated with a similar risk of NACE and higher risk of major bleeding in both sexes. The increase in bleeding complications with edoxaban was attenuated in women.
Study context
- Population
- Patients with AF after successful TAVR658 (47.8%) women
- Participants
- 1,377 patients
- Comparison
- Edoxaban vs vitamin K antagonists (VKA), by sex
- Primary endpoint
- Net adverse CV events (NACE) and major bleeding, on effective time on study medication (safety analysis)
Methodological detailssubgroup analysis by sex
- Subgroup analysis by sex
Primary result
As reported in the abstract
Edoxaban vs VKAHazard ratio (95% CI)
NACE, women
1.16(0.81–1.65)
NACE, men
1.08(0.76–1.53)
Major bleeding, women
1.11(0.69–1.79)
Major bleeding, men
1.75(1.07–2.85)
Further findings
Ischaemic and major bleeding risks, women vs men
- Similar between women and men
Ischaemic complications, by sex
- No treatment-related differences in both sexes
Original publication
Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR. JACC Adv. Published 8 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →